Amarin is still in a holding pattern, waiting for an FDA ruling on its key drug Vascepa's NCE status, but that didn't stop Citigroup from initiating coverage with a buy recommendation and a $20 price target that is a near double from where shares sit today. Watch as Motley Fool health-care analyst David Williamson discusses why Citi likes Amarin so much and whether he agrees with that assessment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.